[A21-138] Venetoclax (acute myeloid leukaemia) - Addendum to commission A21-82
Last updated 02.12.2021
Project no.:
A21-138
Commission:
Commission awarded on 26.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adult patients with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-82 | Venetoclax (acute myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-12-02 A G-BA decision was published.